Physician profile
Luiza Johnson
NPI 1659863991
$1,476.64
in general payments reported to CMS, 2019-2025
32 companies · $170 in 2025
The $170 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $69.70 · 2021: $138 · 2022: $446 · 2023: $290 · 2024: $362 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $822.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $239.52 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $159.54 | 2021-2025 | |
| Pfizer INC. | $114.08 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $82.08 | 2022-2024 | Verquvo, Steglatro, Belsomra |
| Lilly USA, LLC | $75.59 | 2022-2024 | Mounjaro, Zepbound |
| Biohaven Pharmaceutical Holding Company LTD. | $66.83 | 2022 | |
| Mannkind Corporation | $60.31 | 2023-2024 | Afrezza |
| Bayer Healthcare Pharmaceuticals INC. | $56.25 | 2021-2022 | |
| Abbvie INC. | $55.01 | 2022-2024 | |
| Glaxosmithkline, LLC. | $50.44 | 2022-2023 | Shingrix |
| Sanofi-Aventis U.S. LLC | $47.26 | 2023-2024 | |
| Dexcom, INC. | $46.98 | 2024 | Dexcom G6 Transmitter |
| Zealand Pharma US, INC. | $36.63 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.66 | 2025 | Jardiance |
| Amgen INC. | $28.69 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $27.88 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Edwards Lifesciences Corporation | $26.25 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Myovant Sciences INC. | $24.38 | 2021 | |
| Medtronic, INC. | $23.75 | 2025 | Symplicity G3 |
| Lexicon Pharmaceuticals, INC. | $21.74 | 2023 | Inpefa |
| Ascensia Diabetes Care US INC. | $21.72 | 2025 | |
| Boston Scientific Corporation | $19.63 | 2023 | |
| Exeltis, USA INC. | $19.54 | 2022 | |
| Global Blood Therapeutics, INC. | $18.54 | 2020 | |
| Janssen Pharmaceuticals, INC | $18.12 | 2023 | Xarelto |
| Abbott Laboratories | $17.70 | 2024 | Freestyle Libre 3 |
| Hologic Sales and Service, LLC | $17.61 | 2022 | |
| Shield Therapeutics INC | $15.06 | 2022 | |
| Genentech USA, INC. | $14.53 | 2020 | |
| Eisai INC. | $13.25 | 2021 | |
| Therapeuticsmd, INC. | $12.64 | 2022 | |
| Agile Therapeutics, INC. | $12.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luiza Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.